欧洲副肿瘤神经综合征自身抗体检测实验室实践调查:迈向标准化
欧洲自身免疫标准化倡议(EASI)通过问卷评估实验室检测副肿瘤神经综合征(PNS)自身抗体的差异。139家回应实验室中,78%同时进行小脑间接免疫荧光(IIF)和线点印迹法,样本稀释和 conjugate 类型不一致。数字化在线点印迹中普及(87%)但IIF有限(31%)。室内质控执行率IIF为89%、线点印迹为48%。结论存在显著差异,需实验室特定建议以促进标准化。
要点
- 78%实验室联合使用小脑IIF和线点印迹法检测PNS自身抗体。
- 样本稀释(61%一致)和 conjugate 类型(70%一致)存在差异。
- 线点印迹数字化普及(87%),但小脑IIF数字化有限(31%)。
核心结论
- PNS自身抗体检测在方法执行、报告和质量控制方面存在显著差异。
- 引入实验室特定建议可能促进实践标准化并提高诊断质量。
研究设计与样本
- 欧洲自身免疫标准化倡议(EASI)制定问卷,通过UK NEQAS和IfQ Lübeck两个外部质量评估(EQA)提供者分发。
- 调查对象为常规进行PNS自身抗体检测的临床实验室,共139家回应。
主要发现
- 78%实验室同时进行小脑间接免疫荧光(IIF)和线点印迹法,76%检测血清和脑脊液。
- 样本稀释(61%)和 conjugate 类型(70%)一致性可变;抗原组成和报告策略差异导致线点印迹检测变异性。
- 数字化在线点印迹中广泛使用(87%),而小脑IIF仅31%;53%使用因样本类型和抗体请求而异的检测算法。
- 室内质控执行率:IIF 89%,线点印迹48%,主要使用商业质控品;43%参与多个EQA项目;46%(IIF)和42%(线点印迹)通过ISO15189认证,20%计划认证。
- 73%实验室阳性率<6%,表明检验前概率低;仅46%按学科限制检测,但84%获取临床背景,63%与临床医生互动。
临床怎么用
- 实验室应关注PNS自身抗体检测的标准化,统一样本稀释和 conjugate 类型。
- 提高线点印迹法的室内质控执行率,并加强小脑IIF的数字化应用。
- 鼓励实验室获取临床背景并与临床医生互动,以优化检测前概率评估。
局限性
- 调查基于问卷,可能存在回应偏倚。
- 未报告样本量计算或代表性验证,结果可能不适用于所有欧洲实验室。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Detection of paraneoplastic anti-neuronal antibodies (PNS autoantibodies) aids in diagnosing the particular syndrome and guides the search for an underlying tumor. To identify opportunities for harmonization that could enhance diagnostic value, we assessed variability in autoimmune serological testing for PNS across laboratories. METHODS: The European Autoimmunity Standardisation Initiative (EASI) developed a questionnaire addressing testing methods, digital tools, interpretation, clinical context, and quality assurance. This was distributed through two external quality assessment (EQA) providers (UK NEQAS and IfQ Lübeck) to clinical labs routinely performing PNS autoantibody assays. RESULTS: Among 139 responding laboratories, 78 % perform both cerebellum indirect immunofluorescence (IIF) and line/dot blot assays on serum and cerebrospinal fluid (76 %). Alignment on sample dilution (61 %) and conjugate type (70 %) is variable. Differences in antigen composition and reporting strategies contribute to variability in line/dot blot testing. Digitization is widespread for line/dot blot data (87 %) but limited for cerebellum IIF (31 %). About 53 % use testing algorithms that vary by sample type and requested antibodies. Internal quality control is performed by 89 % (IIF) and 48 % (line/dot blot), mainly using commercial controls. Nearly half (43 %) participate in multiple EQA programs; 46 % (IIF) and 42 % (line/dot blot) have ISO15189 certification, with 20 % planning certification. Positivity rates are low (<6 % in 73 % of labs), indicating low pre-test probability. While only 46 % restrict testing by discipline, most labs access clinical context (84 %) and interact with clinicians (63 %). CONCLUSIONS: Considerable variability exists in PNS autoantibody assay execution, reporting, and quality control. Introducing lab-specific recommendations may harmonize practices and improve diagnostic quality.
引用
- Oyaert M, Schreurs M, Goncalves D, et al. Towards harmonization of autoantibody detection in relation to paraneoplastic neurological syndromes (PNS): a European Survey on laboratory practices. Clin Chem Lab Med. 2025. PMID: 41047952. doi:10.1515/cclm-2025-1030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。